Home CONTACT Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.1, p.65–69, 2019

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.120, No.1, p.65–69, 2019

Title: Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis
Author: S. Colak, A. Omma, S. C. Sandikci, C. Yucel, T. Omma, T. Turhan

Abstract: OBJECTIVES: To examine the relationship between disease activity and vaspin, neutrophil gelatinase-associated lipocalin (NGAL) and apolipoprotein levels in patients with psoriatic arthritis (PsA).
BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis, which is related with psoriasis. Adipokines are the mediators which play a role in metabolic homeostasis and inflammatory conditions.
METHODS: The levels of vaspin, NGAL, apolipoproteins and their correlations with disease activity were compared in 50 psoriatic arthritis patients and 36 healthy controls.
RESULTS: The levels of vaspin, NGAL and apolipoprotein B/A1 ratio were significantly higher in the patient group (p 0.05).
CONCLUSION: This is the first study to have compared vaspin and NGAL levels in patients with PsA. Vaspin and NGAL can be used as a biomarker in PsA. Vaspin, NGAL and dyslipoproteinemia are not correlated with disease activity (Tab. 3, Ref. 63).

Keywords: apolipoprotein, disease activity, neutrophil gelatinase-associated lipocalin, psoriatic arthritis, vaspin
Published online: 22-Jan-2019
Year: 2019, Volume: 120, Issue: 1 Page From: 65, Page To: 69
doi:10.4149/BLL_2019_010


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.